New blood test screening targets hidden cancer in black communities
NCT ID NCT05831358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a blood screening program to find multiple myeloma and its early stages (MGUS and smoldering myeloma) in Black adults aged 50 and older. Participants get a simple blood test and fill out questionnaires about their experience and knowledge of the disease. Those with abnormal results receive help navigating follow-up care. The goal is to see if community-based screening and patient navigation can improve early detection and reduce cancer disparities.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blood test for monoclonal protein analysis
What this could lead to
If successful, this screening program could help detect multiple myeloma earlier in high-risk communities, potentially improving outcomes and reducing health disparities.
What could go wrong
This is a small pilot study focused on feasibility and community reception, not on proving that screening saves lives. It may not show a clear benefit or be scalable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States